Targeting integrated metabolic and epigenetic pathways in childhood ependymomas
针对儿童室管膜瘤的综合代谢和表观遗传途径
基本信息
- 批准号:10659244
- 负责人:
- 金额:$ 58.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-05 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant TherapyAdolescentAdultBiologicalBiological AssayBiologyCell LineCell ProliferationCellsChIP-seqChildChildhood EpendymomaChromatinCitric Acid CycleClassificationClinicalClinical TrialsClinical Trials DesignCritiquesDNADNA Modification ProcessDataDevelopmentDiseaseEZH2 geneEnzymesEpendymomaEpigenetic ProcessExhibitsGene ExpressionGenesGeneticGenomicsGerm-Line MutationGlucoseGlycolysisGoalsHeterogeneityHexokinase 2HistonesIn VitroInfantInterruptionIsocitrate DehydrogenaseIsotopesKnowledgeLinkLysineMagnetic Resonance SpectroscopyMalignant NeoplasmsMeasuresMediatingMetabolicMetabolic PathwayMetabolismMethyltransferaseModificationMolecularMorbidity - disease rateMutationOncogenesOncogenicOperative Surgical ProceduresPathogenesisPathway interactionsPatientsPosterior FossaProductionPrognosisProteinsProtocols documentationRadiationRecurrenceRegulationResearchSomatic MutationTherapeuticTreatment EfficacyTricarboxylic AcidsWorkalpha ketoglutaratecofactorcombatdemethylationdesigneffective therapyenzyme pathwaygenome-wideglucose metabolismhindbrainhistone modificationin vivoinhibitormalemetabolic imagingmitochondrial metabolismmortalityneoplastic cellnon-invasive monitornovelnutrient metabolismoverexpressionpatient derived xenograft modelpharmacologicprogramsprotein expressionsexspectroscopic imagingstandard caretargeted therapy trialstherapeutic developmenttherapeutic effectivenesstumortumor growthuptake
项目摘要
Ependymomas in children mainly arise in the hindbrain/ posterior fossa (PF) and carry high morbidity and
mortality. Despite decades of clinical trials, mainstay treatment still remains surgery and adjuvant radiation,
that are not curative. PF ependymomas are unique as more than 80% of tumors do not bear recurrent genetic
alterations. Instead, they are epigenetically driven. They are classified into group-A (PFAs) tumors defined by
an epigenetic state of global reduction of the repressive mark H3K27me3 and group-B (PFBs) tumors that do
not show a reduction in H3K27me3. PFAs mainly occur in infants and young children and exhibit a dismal
prognosis, while PFB tumors are mainly observed in adolescents and adults and bear an excellent prognosis.
Reduced H3K27me3 in PFAs is mediated by a protein termed EZHIP (EZH inhibitory protein) that suppresses
the function of the H3K27 methyltransferase EZH2. However, how EZHIP drives the pathogenesis of PFAs
remains unknown. A central hallmark of cancer is reprograming of cellular metabolism by oncogenes, which
enables increased uptake and metabolism of nutrients such as glucose by tumors. Moreover, Metabolic and
epigenetic pathways are intimately linked and metabolites can directly impact epigenetic modifications. For
example, the metabolite α-ketoglutarate (αKG) is a critical cofactor for the H3K27 histone lysine demethylases
(KDMs) that can drive global reduction of H3K27me3. Our preliminary data show that EZHIP enhances
glycolysis and TCA cycle to produce high αKG levels. Our overarching hypothesis is that EZHIP epigenetically
rewires cellular metabolism to increase αKG production that is required to maintain low H3K27me3 levels.
Consequently, suppressing this epigenetic/ metabolic pathway will be therapeutic. Two specific aims will
address our hypothesis: Aim 1. Elucidate the molecular mechanisms by which EZHIP enhances glycolysis and
TCA cycle metabolism. Aim 2. Determine the therapeutic potential of targeting an integrated metabolic/
epigenetic pathway to combat these tumors. The combination of these two aims will address significant gaps in
our understanding of PFAs and lay the groundwork to develop effective treatments.
儿童室管膜瘤主要发生在后脑/后颅窝(PF),发病率高,
mortality.尽管经过了几十年的临床试验,主要的治疗方法仍然是手术和辅助放疗,
是没有疗效的。PF室管膜瘤是独特的,因为超过80%的肿瘤不携带复发的遗传基因,
改变。相反,它们是表观遗传驱动的。它们被分类为A组(PFA)肿瘤,其定义如下:
抑制性标记H3 K27 me 3和B组(PFB)肿瘤的整体减少的表观遗传状态,
没有显示H3 K27 me 3的减少。PFAs主要发生在婴儿和幼儿中,
PFB肿瘤主要见于青少年和成人,预后良好。
PFAs中H3 K27 me 3的减少由称为EZHIP(EZH抑制蛋白)的蛋白介导,该蛋白抑制
H3 K27甲基转移酶EZH 2的功能。然而,EZHIP如何驱动PFAs的发病机制,
仍然未知。癌症的一个中心标志是癌基因对细胞代谢的重编程,
能够增加肿瘤对营养物如葡萄糖的摄取和代谢。此外,代谢和
表观遗传途径密切相关,代谢物可直接影响表观遗传修饰。为
例如,代谢产物α-酮戊二酸(αKG)是H3 K27组蛋白赖氨酸脱甲基酶的关键辅因子
(KDM)可以推动H3 K27 me 3的全球减少。我们的初步数据显示,EZHIP增强了
糖酵解和TCA循环产生高αKG水平。我们的总体假设是,EZHIP表观遗传
重新连接细胞代谢以增加维持低H3 K27 me 3水平所需的αKG产生。
因此,抑制这种表观遗传/代谢途径将是治疗性的。两个具体目标将
解决我们的假设:目标1。阐明EZHIP增强糖酵解的分子机制,
TCA循环代谢。目标2.确定靶向整合的代谢/
表观遗传途径来对抗这些肿瘤。这两个目标的结合将解决以下方面的重大差距:
我们对PFAs的理解,并为开发有效的治疗方法奠定基础。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Deepak Nagrath其他文献
Deepak Nagrath的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Deepak Nagrath', 18)}}的其他基金
Targeting integrated metabolic and epigenetic pathways in childhood ependymomas
针对儿童室管膜瘤的综合代谢和表观遗传途径
- 批准号:
10536996 - 财政年份:2022
- 资助金额:
$ 58.51万 - 项目类别:
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy
源自人 IPS 细胞的微型肝脏用于脂肪变性建模和治疗
- 批准号:
10445352 - 财政年份:2014
- 资助金额:
$ 58.51万 - 项目类别:
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy
源自人 IPS 细胞的微型肝脏用于脂肪变性建模和治疗
- 批准号:
10623305 - 财政年份:2014
- 资助金额:
$ 58.51万 - 项目类别:
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy
源自人 IPS 细胞的微型肝脏用于脂肪变性建模和治疗
- 批准号:
10297425 - 财政年份:2014
- 资助金额:
$ 58.51万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 58.51万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 58.51万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 58.51万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 58.51万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 58.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 58.51万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 58.51万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 58.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 58.51万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 58.51万 - 项目类别:
Operating Grants